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Objectives: To describe a methodological framework for the economic evalua-
tion of health care programmes that addresses effects on unfair health inequality 
as well as overall health. The framework is designed to highlight the social value 
judgements required to define unfair health inequality and how these impact on the 
estimated level of inequality, and is distinct from equity weighting or multi-criteria 
decision analysis. Application of the framework comprises characterisation and 
quantification of the distribution of health, and this is illustrated using an existing 
decision model evaluating a bowel cancer screening programme. MethOds: The 
decision model of bowel cancer screening is restructured using additional infor-
mation on the distributions of screening uptake, baseline health levels, quality-
adjusted life expectancy and health opportunity costs in order to estimate the 
health distribution resulting from alternative bowel cancer screening policies. 
Standard screening is compared to two re-design policies wherein reminders are 
used to increase uptake. Different sets of social value judgements are applied to 
explore the robustness of the results, using different approaches to measuring ine-
quality and to adjusting health distributions for fair sources of inequality. Results: 
A universal reminder to participate in bowel cancer screening results in the greatest 
improvement in total population health, but increases inequality compared to no 
reminder or targeted reminders. Targeting reminders by deprivation and ethnicity 
reduces health inequality. The choice between screening policies depends on the 
type and level of inequality aversion and on the value judgements about which 
sources of health inequality are unfair. cOnclusiOns: The framework imposes 
additional data requirements and requires that decision makers consider sup-
plementary value judgements compared to standard cost-effectiveness analysis. 
Differential uptake of screening results in significant, potentially avoidable, health 
inequalities. This framework can provide decision makers with useful information 
to help address such inequalities while appropriately addressing any trade off with 
improving overall health.
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Objectives: In Korea, the Positive List System was adopted in the end of 2006 
and the cost-effectiveness had been important in decision making process 
for reimbursement. We tried to check the appraisal results. MethOds: Total 
of 5-years decision-making from 2007 to 2011 were reviewed and classified in 
several categories according to relative effectiveness and submission type of 
cost-effectiveness. Results: Among 219 results which were made decision 
there were 149 recommendations(68%) for listing. Fifty submissions were cost-
effectiveness(utility) analysis report but 26 submissions of those were improved 
relative effectiveness compared to the comparator. Twenty-four drugs were sub-
mitted CEA or CUA even though they didn’t have evidence for improvement. If 
there was no evidence for the relative effectiveness or the new drug was inferior 
HIRA decided not to list. If new drug had evidence for non-inferiority it could be 
evaluated by cost-minimization analysis. Eleven drugs were decided to be listed 
among 12 submissions by CMA. There were 9 essential drugs to be appraised 
for 5 years. cOnclusiOns: The most important factor in decision-making for 
reimbursement was relative effectiveness and the method of economic evalua-
tion was determined by drug’s relative effectiveness. In deciding acceptability in 
cost-effectiveness results the other factors are considered whether the drug used 
in severe disease or it was orphan drug, etc.
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Objectives: Breast cancer generates a considerable economic burden. This study 
aims to quantify health care resource utilization and health care expenditures of 
breast cancer patients in The Netherlands. MethOds: A bottom-up cost-analysis 
was conducted using health insurance data retrieved from the AGIS Health Database 
in The Netherlands containing information on health care usage and –expendi-
tures. Additionally, we estimated cost of in-hospital breast cancer medication in 
a top-down manner, based on Dutch National Breast Cancer treatment guide-
lines. Incident breast cancer cases (2008-2010) were included based on Diagnosis-
Treatment-Combinations (DTC) codes containing the diagnosis of breast cancer. 
Health care resource utilization and expenditures were examined per phase of treat-
ment (the year of diagnosis, second year, third year and last year of life). Results: 
A total of 3494 newly diagnosed breast cancer patients were identified in the AGIS 
database, with an average age of 63 years at diagnosis. During the follow-up period, 
220 patients died. Health care expenditures of Dutch breast cancer patients insured 
at AGIS were on average € 17.120 per case in the year of diagnosis, € 9.014 in the 
second year, € 5.499 in the third year and € 14.900 in the last year of life. The major-
ity of the expenditures were related to health care utilized in the hospital setting. 
Additional costs of treatments with expensive drugs varied between € 15.462 and 
€ 38.877, depending on the type of treatment. cOnclusiOns: Health care usage and 
expenditures of Dutch breast cancer patients are substantial in the year of diagnosis, 
decrease in the second and third year after diagnosis, and then increase again in 
the last year of life. Treatment with expensive drugs adds a substantial cost burden.
Objectives: To develop a decision-analytic model describing the current course of 
disease, including the available treatments, in metastatic colorectal cancer to serve 
as a baseline for the analyses of new developments. MethOds: A disease model 
was constructed containing six disease states, namely ‘first-line treatment’, ‘pro-
gression of disease after first-line’,’ second-line treatment’, ‘progression of disease 
after second-line’, ‘third-line treatment’ and ‘death’. Time spent in each state was 
predicted using log-logistic, log-normal or Weibull survival models, utilizing simu-
lated characteristics. All survival models and simulated characteristics were based 
on patient-level data, provided by the CAIRO trial (n= 820). The model was validated 
by comparing various outcome parameters with the original data. Results: The 
overall survival of the simulated cohort resulted in a median survival of 498 days. 
The original patient level data had a median OS of 508 days (95% CI: 463- 545). For 
the subgroups age and treatment line data continued to match consistently with 
patient-level data. Patients treated with sequential therapy in the RCT had an OS of 
492 days (95% CI 416-557), the model predicted an OS of 489 days. Patients in the RCT 
with combination therapy had an OS of 525 days (95%CI 442-591days), the model 
predicted 509 days OS. Similar results were achieved in other subgroups and for 
various other outcome measures. cOnclusiOns: The model constructed during 
this study is a good basis on which to model the effectiveness and cost-effectiveness 
of numerous new treatment options, including expensive drugs. It will also allow 
- in future - for the evaluation of these treatment options while accounting for the 
heterogeneous nature of colorectal cancer As such this model offers a method to 
aid in determining the optimal sequence of treatments for patients with metastatic 
colorectal cancer, both in terms of costs and effects.
PCN190
stAge-BAseD utilizAtioN oF ChemotherAPy AgeNts iN A CANADiAN 
BreAst CANCer PoPulAtioN
Mittmann N.1, Seung S.J.1, Porter J.1, Rangrej J.1, Liu N.1, Trudeau M.2, DeAngelis C.1, Hoch J.S.3, 
Leighl N.4, Earle C.C.5
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Sunnybrook Health Science Centre, 
Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Princess Margaret Hospital/
University Health Network, Toronto, ON, Canada, 5Cancer Care Ontario / Institute for Cancer 
Research, Toronto, ON, Canada
Objectives: To describe the utilization of chemotherapy agents administered 
to women with a diagnosis of breast cancer, by stage of disease. MethOds: 
Chemotherapy utilization was extracted from two databases with population-
level coverage [New Drug Funding Program (NDFP) and Activity Level Reporting 
(ALR) data] for women diagnosed with breast cancer between January 1, 2005 and 
December 31, 2009 and resident in Ontario, Canada. NDFP included expensive 
antineoplastics. ALR included only intravenous antineoplastics for agents admin-
istered at cancer centres. Each entry in the database represented one exposure to 
an antineoplastic medication administered and funded by the province. Hormonal 
therapies were not included in this analysis. All duplicate entries (same patient, 
same drug, same date of administration, same dose) were excluded. Overall utiliza-
tion and utilization by stage of disease were determined. Chemotherapy regimen 
utilization was not analyzed, only individual drug use was. Results: There were 
39,656 breast cancer cases (34.4% Stage I; 31.8% Stage II; 12.0% Stage III; 3.9% 
Stage IV; 17.9% Unstaged) with a mean age of 61.6 ± 14.0 years. Among all cases 
(staged and unstaged), 17,383 (43.8%) received chemotherapy. The most common 
drugs administered across the entire cohort were cyclophosphamide (68.4%), doc-
etaxel (52.8%), epirubicin (47.3%), fluorouracil (36.2%), doxorubicin (31.6%) and 
traztuzumab (24.3%). The drug utilization for Stage I/II was cyclophosphamide 
(72.9%), docetaxel (52.0%), epirubicin (49.6%), fluorouracil (37.9%), doxorubicin 
(31.2%), paclitaxel (23.0%) and traztuzumab (22.8%). For Stage III/IV utilization 
was as follows: cyclosphosphamide (68.3%), docetaxel (62.4%), epirubicin (45.6%), 
doxorubicin (36.1%), traztuzumab (27.8%) and paclitaxel (26.0%). cOnclusiOns: 
This frequency distribution of chemotherapeutic agents provides population level 
data on the management of breast cancer, by stage. Future work will involve cost-
ing of these medications from a population perspective.
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Objectives: Clinically significant prostate cancer is characterized by the growth 
of a tumor of more than 20 cc of cancerous cells within the prostate gland. 
Literature suggests significant disparities in prostate cancer prevalence and out-
comes between Whites and African-Americans resulting in greater health services 
utilization. This study assessed the count of health care visits between White and 
African American prostate cancer patients. MethOds: This cross-sectional study 
used data from the 2010 Medical Expenditure Panel Survey. Negative binomial 
regression models were used to estimate the count of health services including 
emergency department visits, outpatient services and inpatient services associ-
ated with race in patients with prostate cancer while controlling for age and count 
of comorbidities. Patients who were not White or African-American were excluded 
due to the small numbers. Results: The total sample consisted of 141 patients, of 
which 104 were White and 37 were African-Americans. Being White was associated 
with 43% less use of emergency services compared to being an African American 
while adjusting for age and comorbidities (IRR 0.57; 95% CI 0.33-0.97). Similarly, 
being White was associated with a 44% lower count of outpatient service use (IRR 
0.56; 95% CI 0.32-0.99). No difference was found with inpatient services, most 
likely due to a low number of events. cOnclusiOns: Being White was associated 
with less emergency and routine health care visits compared to being an African 
American, suggesting a disparity may exist among prostate cancer patients. More 
research should explore the sources of the disparity and whether this translates 
into other health care services like access to treatments.
